Table 3.
Clinical presentation of the COVID-19 groups
| Studied variables | COVID-19 groups | Test f sig. | P value | |
|---|---|---|---|---|
| Group I N = 295 |
Group II N = 103 |
|||
| Dry cough n (%) | 74 (25.1%) | 81 (78.6%) | 92.09 | < 0.001** |
| Tachypnea n (%) | 70 (23.7%) | 96 (93.2%) | 39.39 | < 0.001** |
| Rhinorrhea | 73 (24.7%) | 0 (0.0%) | 30.17 | < 0.001** |
| Sore throat n (%) | 73 (24.7%) | 0 (0.0%) | 31.21 | < 0.001** |
| Headache n (%) | 165 (55.9%) | 75 (72.8%) | 9.09 | 0.003* |
| Fatigue n (%) | 177 (60.0%) | 53 (51.5%) | 2.58 | 0.13 |
| Vomiting or diarrhea n (%) | 127 (43.1%) | 11 (10.7%) | 35.32 | < 0.001** |
| Fever n (%) | 274 (92.9%) | 103 (100%) | 7.74 | 0.005* |
| Shock n (%) | 17 (5.7%) | 70 (68.0%) | 57.43 | < 0.001** |
| Hypoxia n (%) | 33 (11.2%) | 103 (100%) | 267.7 | < 0.001** |
| Acute pancreatitis manifestations | 0 (0.0%) | 5 (4.8%) | 14.5 | < 0.001** |
| Deep venous thrombosis manifestations | 5 (1.7%) | 0 (0.0%) | 1.77 | 0.18 |
| Kawasaki like diseases | 0 (0.0%) | 4 (3.9%) | 11.77 | 0.001** |
| Fever duration after admission, days | ||||
| Mean ± SD | 7.39 ± 3.97 | 9.76 ± 4.25 | U | |
| Median (Range) | 7 (2–16) | 6 (6–20) | 1.39 | 0.16 |
X Mean, SD standard deviation, U Mann-Whitney U test, X2 Chi-square test
*Significant ** highly significant